HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology

• DOI: 10.1101/gr.221218.117
• Publication Date: 2017-07-19T00:45:21Z
• Authors: Raunak Shrestha; Ermin Hodzic; Thomas Sauerwald; Phuong Dao; Kendric Wang; Jake Yeung; Shawn Anderson; Fabio Vandin; Gholamreza Haffari; Colin C. Collins; S. Cenk Sahinalp
• Keywords: DNA Copy Number Variations; 0206 medical engineering; Method; Computational Biology; Breast Neoplasms; Genomics; 02 engineering and technology; 3. Good health; Mutation; Humans; Female; Protein Interaction Maps; Transcriptome; Software

Prioritizing molecular alterations that act as drivers of cancer remains a crucial bottleneck in therapeutic development. Here we introduce HIT'nDRIVE, a computational method that integrates genomic and transcriptomic data to identify a set of patient-specific, sequence-altered genes, with sufficient collective influence over dysregulated transcripts. HIT'nDRIVE aims to solve the “random walk facility location” (RWFL) problem in a gene (or protein) interaction network, which differs from the standard facility location problem by its use of an alternative distance measure: “multihitting time,” the expected length of the shortest random walk from any one of the set of sequence-altered genes to an expression-altered target gene. When applied to 2200 tumors from four major cancer types, HIT'nDRIVE revealed many potentially clinically actionable driver genes. We also demonstrated that it is possible to perform accurate phenotype prediction for tumor samples by only using HIT'nDRIVE-seeded driver gene modules from gene interaction networks. In addition, we identified a number of breast cancer subtype-specific driver modules that are associated with patients’ survival outcome. Furthermore, HIT'nDRIVE, when applied to a large panel of pan-cancer cell lines, accurately predicted drug efficacy using the driver genes and their seeded gene modules. Overall, HIT'nDRIVE may help clinicians contextualize massive multiomics data in therapeutic decision making, enabling widespread implementation of precision oncology.